{"id":2485,"date":"2026-02-01T15:26:17","date_gmt":"2026-02-01T15:26:17","guid":{"rendered":"https:\/\/sorescolab.com\/?page_id=2485"},"modified":"2026-02-01T15:37:01","modified_gmt":"2026-02-01T15:37:01","slug":"validation-dermatologique-sgs","status":"publish","type":"page","link":"https:\/\/sorescolab.com\/en\/validation-dermatologique-sgs\/","title":{"rendered":"Validation Dermatologique SGS"},"content":{"rendered":"
\n\t
\n\t\t
\n\t\t\t\r\n\r\n\r\n \r\n \r\n
\r\n Rapport d'Essai N\u00b0 5243 \u2014 SGS Tunisie S.A. (05\/08\/2014)\r\n \r\n L'efficacit\u00e9 objectiv\u00e9e
\r\n par la mesure\r\n clinique<\/span>\r\n <\/h1>\r\n

\r\n \u00c9valuation de la tol\u00e9rance cutan\u00e9e aig\u00fce de l'Huile des Pharaons (RN14-13455.001<\/strong>)
\r\n Lot n\u00b0 070314V \u2014 Application 25\u00b5l sous patch occlusif 48h.\r\n <\/p>\r\n \r\n T\u00e9l\u00e9charger le rapport complet (PDF)<\/span>\r\n \u2193<\/span>\r\n <\/a>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n

\r\n
\r\n
\r\n
\r\n \r\n Protocole de l'\u00e9tude<\/h2>\r\n

\r\n Cette \u00e9tude a \u00e9t\u00e9 men\u00e9e dans des conditions contr\u00f4l\u00e9es afin d'\u00e9valuer la tol\u00e9rance et\r\n l'efficacit\u00e9 de notre formule exclusive.\r\n <\/p>\r\n

    \r\n \r\n Type d'\u00e9tude<\/strong>\r\n Patch-test occlusif (48h)<\/span>\r\n <\/li>\r\n \r\n Lieu & Supervision<\/strong>\r\n Unit\u00e9 Clinique \u2014 Dr M. Nowakowska<\/span>\r\n <\/li>\r\n \r\n Dispositif<\/strong>\r\n Finn Chambers\u00ae \u00d88mm (50mm\u00b2)<\/span>\r\n <\/li>\r\n \r\n Dose<\/strong>\r\n 25 \u00b5l (Concentration 100%)<\/span>\r\n <\/li>\r\n \r\n Zone<\/strong>\r\n Scapulaire (Dos)<\/span>\r\n <\/li>\r\n \r\n Panel<\/strong>\r\n 10 Sujets (6F \/ 4H) \u2014 \u00c2ge moy. 49 ans<\/span>\r\n <\/li>\r\n <\/ul>\r\n <\/div>\r\n \r\n

    Objectifs\r\n principaux<\/h3>\r\n
    \r\n
    \r\n 1<\/span>\r\n

    D\u00e9terminer la tol\u00e9rance cutan\u00e9e\r\n exp\u00e9rimentale apr\u00e8s application unique.<\/p>\r\n <\/div>\r\n

    \r\n 2<\/span>\r\n

    Lecture des r\u00e9actions cutan\u00e9es \u00e0 30\r\n minutes et \u00e0 24 heures.<\/p>\r\n <\/div>\r\n

    \r\n 3<\/span>\r\n

    Calcul de l'Indice d'Irritation\r\n Moyen (I.I.M.).<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n

    \r\n
    \r\n \r\n R\u00e9partition des Scores (0-3)<\/h3>\r\n\r\n
    \r\n
    \r\n
    0\r\n <\/div>\r\n
    \u00c9ryth\u00e8me
    (Rougeurs)<\/div>\r\n <\/div>\r\n
    \r\n
    0\r\n <\/div>\r\n
    \u0152d\u00e8me
    (Gonflement)<\/div>\r\n <\/div>\r\n
    \r\n
    0\r\n <\/div>\r\n
    S\u00e9cheresse<\/div>\r\n <\/div>\r\n
    \r\n
    0\r\n <\/div>\r\n
    V\u00e9sicules<\/div>\r\n <\/div>\r\n <\/div>\r\n \r\n \u00c9chelle de notation (Score visuel) :<\/strong>
    \r\n 0 : Absent | 0.5 : Tr\u00e8s l\u00e9ger (Rose \u00e0 peine perceptible) | 1 : L\u00e9ger (Rose net)
    \r\n 2 : Clair (\u00c9ryth\u00e8me sur toute la surface) | 3 : S\u00e9v\u00e8re (\u00c9ryth\u00e8me intense, \u0153d\u00e8me)\r\n <\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n
    \r\n
    \r\n \r\n Conditions Rigoureuses de S\u00e9lection\r\n <\/h3>\r\n \r\n
    \r\n Crit\u00e8res d'Exclusion\r\n M\u00e9dicale<\/strong>\r\n
      \r\n
    • Femmes enceintes ou allaitantes.<\/li>\r\n
    • Pathologies cutan\u00e9es sur la zone (Psoriasis, Ecz\u00e9ma, Vitiligo, Acn\u00e9).<\/li>\r\n
    • Grains de beaut\u00e9 ou pilosit\u00e9 excessive sur la zone dorsale.<\/li>\r\n <\/ul>\r\n <\/div>\r\n
      \r\n Restrictions M\u00e9dicales (Avant\r\n test)<\/strong>\r\n
        \r\n
      • Pas d'anti-inflammatoires\/antibiotiques (1 sem).<\/li>\r\n
      • Pas de cortico\u00efdes (4 sem).<\/li>\r\n
      • Pas de r\u00e9tino\u00efdes\/immunosuppresseurs (6 mois).<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/div>\r\n \r\n Restrictions Volontaires (48h) :<\/strong> Interdiction absolue de mouiller la zone, d'exposer au\r\n soleil (UV), ou d'appliquer tout autre produit cosm\u00e9tique.\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n
        \r\n
        \r\n
        \r\n

        R\u00e9sultats\r\n Cl\u00e9s<\/h2>\r\n

        Synth\u00e8se des mesures (I.I.M.) \u00e0 30 min et 24h<\/p>\r\n <\/div>\r\n\r\n

        \r\n \r\n \r\n \r\n 0.00<\/span>\r\n <\/div>\r\n \r\n I.I.M. (30 min)<\/div>\r\n

        Indice d'Irritation Moyen nul apr\u00e8s 30 minutes. Aucune\r\n r\u00e9action d'\u00e9ryth\u00e8me ou d'\u0153d\u00e8me.<\/p>\r\n <\/div>\r\n \r\n \r\n \r\n NON<\/span>\r\n <\/div>\r\n \r\n Classement<\/div>\r\n

        Class\u00e9 NON IRRITANT<\/strong> selon l'\u00e9chelle de\r\n l'\u00e9tude (I.I.M. < 0.08).<\/p>\r\n <\/div>\r\n \r\n \r\n \r\n 0.00<\/span>\r\n <\/div>\r\n \r\n I.I.M. (24 heures)<\/div>\r\n

        Indice d'Irritation Moyen maintenu \u00e0 0.00 apr\u00e8s 24\r\n heures. Tol\u00e9rance confirm\u00e9e.<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n

        \r\n
        \r\n
        <\/div>\r\n \r\n Conclusion de l'expert<\/h2>\r\n \r\n \"Dans les conditions exp\u00e9rimentales adopt\u00e9es, le produit HUILE DES PHARAONS (RN14-13455.001) est\r\n NON IRRITANT<\/strong> apr\u00e8s une application unique sous patch occlusif pendant 48 heures\r\n chez un panel de 10 volontaires adultes.\"\r\n <\/blockquote>\r\n \r\n \r\n Visualiseur de document<\/span>\r\n R\u00e9f. 5243<\/span>\r\n <\/div>\r\n